Effects of different doses of propofol on hepatic and renal function in morbid obese patients undertook bariatric surgery

doi:10.3877/cma.j.issn.2095-9605.2019.04.004

Abstract

Abstract:

Objective

To compare the effects of propofol anesthesia on liver and kidney function after weight-loss surgery within two different dose.

Methods

23 ASA class I or II morbid obese patients (BMI≥35 kg/m²) undergoing bariatric surgery will be randomly divided into total body weight grope (group I involved 11 cases) and lean body weight group (group II involved 12 cases) . Another 6 ASA I- II normal weight patients (BMI of 18.5-24 kg/m²) undergoing laparoscopic surgery were enrolled for contrast (group III) . They received defferent dose propofol for anesthesia. Renal and hepatic functions were detected before and on the 6h (T1), 24h (T2), and 72h (T3) after withdrawal propofol, such as serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB), urea nitrogen (BUN) and β2-microglobulin (β2-MG) and so on.

Results

There were no significant differences in liver function indexes such as AST and ALT at different time point in three groups. Compared with T1, ALB and BUN in the three groups of patients was significantly decrease in T3 and T4 (P<0.05); Compared with T1, B2-microglobulin in the three groups decreased significantly in T2-T3 (P<0.05).

Conclusions

For morbidly obese patients, two different doses of propofol anesthesia have no significant effect on liver and kidney function in morbidly obese patients. To reduce the complications of propofol infusion syndrome, LBW is recommended as the dose of propofol.

Key words: Propofol, Obesity, Drug dosage, Hepatic and renal function, General anesthesia

Guifeng Pan, Xuemei Peng. Effects of different doses of propofol on hepatic and renal function in morbid obese patients undertook bariatric surgery[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2019, 05(04): 196-200.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2019.04.004

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2019/V05/I04/196

Figures/Tables 3

References 20

[1]	Kam PC, Cardone D. Propofol infusion syndrome[J]. Anaesthesia, 2007, 62(7): 690-701.
[2]	潘阳阳,乔南南,赵芳玉, 等. 病态肥胖患者丙泊酚的药代动力学及麻醉应用研究进展[J]. 国际麻醉学与复苏杂志, 2019, 40(3): 286-288.
[3]	SantAnna MJ, Carvalhal RF, Oliveira FD, et al. Respiratory mechanics of patients with morbid obesity[J]. Jornal Brasileiro de Pneumologia, 2019, 45(5): e20180311.
[4]	Robinson PD. Obesity and its impact on the respiratory system[J]. Paediatric Respiratory Reviews, 2014, 15(3): 219-226.
[5]	De Jone A, Verzilli D, Geniez M, et al. Why is the morbidly obese patient at high risk of anesthetic complications? [J]. La Presse Médicale, 2018, 47(5): 453-463.
[6]	Murphy, GS, Szokol JW, Marymont JH, et al., Residual Neuromuscular Blockade and Critical Respiratory Events in the Postanesthesia Care Unit[J]. Anesthesia & Analgesia, 2008, 107(1): 130-137.
[7]	Bahattin T, Yonca OP, Asude A, et al. Retrospective Evaluation of Patients who Underwent Laparoscopic[J]. Bariatric Surgery, 2018, 46(4): 297-304.
[8]	Janmahasatian S, Duffull DS, Ash S, et al. Quantification of Lean Bodyweight[J]. Clinical Pharmacokinetics, 2005, 44(10): 1051-1065.
[9]	Wang YS, Qiu RG, Kong GY, et al. Effects of propofol combined with remifentanil anesthesia on the NO, endothelin and inflammatory cytokines in the plasma of patients with liver cirrhosis during the perioperative period[J]. Experimental and Therapeutic Medicine, 2019, 17(5): 3694-3700
[10]	Lee HJ, Bae JY, Kwon YS, et al. General Anesthetic Agents and Renal Function after Nephrectomy[J]. Joural of Clinical Medicine, 2019, 8(10): 1530
[11]	廖武豪,邹启荣,蒋德英, 等. 不同麻醉诱导剂量丙泊酚对病态肥胖患者心脏泵功能的影响[J]. 实用医学杂志, 2017, 33(24): 4145-4148.
[12]	Braz MG, Braz LG, Freire CM, et al. Isoflurane and Propofol Contribute to Increasing the Antioxidant Status of Patients During Minor Elective Surgery[J]. Medicine (Baltimore), 2015, 94(31): 1266.
[13]	Yagmurdur H, Binnetoglu K, Astarci HM, et al. Propofol attenuates cytokine-mediated upregulation of expression of inducible nitric oxide synthase and apoptosis during regeneration post-partial hepatectomy[J]. Acta Cirurgica Brasileira, 2017, 32(5): 396-406.
[14]	罗辉遇,谢长江,刘卫江, 等. 大手术重症患者血清白蛋白水平的变化及临床意义[J]. 实用医学杂志, 2006, 22(12): 1400-1401.
[15]	Lnker LA, Tighiouart H, Coresh J, et al. GFR estimation using β-trace protein and β2-microglobulin in CKD[J]. Am J Kidney Dis, 2016, 67(1): 40-48.
[16]	Tian HT, Duan XH, Yang YF, et al. Effects of propofol or sevoflurane anesthesia on the perioperative inflammatory response, pulmonary function and cognitive function in patients receiving lung cancer resection[J]. European Review for Medical & Pharmacological Sciences, 2017, 21(23): 5515.
[17]	Han C, Ding W, Jiang W, et al. A comparison of the effects of midazolam, propofol and dexmedetomidine on the antioxidant system: A randomized trial[J]. Experimental And Therapeutic Medicine, 2015, 9(6): 2293-2298.
[18]	Tao T, Li CL, Yang WC, et al. Protective effects of propofol against whole cerebral ischemia/reperfusion injury in rats through the inhibition of the apoptosis-inducing factor pathway[J]. Brain Research, 2016, 1644: 9-14.
[19]	Roh GU, Song Y, Park J, et al. Effects of propofol on the inflammatory response during robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled study[J]. Scientific Reports, 2019, 9: 5242.
[20]	Gallego L, Soro M, Alvari OA, et al. Renal and hepatic integrity in long-term sevoflurane sedation using the anesthetic conserving device: A comparison with intravenous propofol sedation in an animal model[J]. Revista Española de Anestesiología y Reanimación (English Edition), 2015, 62(4): 191-203.

参数	I组（n=12）	II组（n=11）	III组（n=6）
年龄	30.9±7.5	30.2±7.3	28.8±10.8
体重(kg)	121.6±43.6	124.1±26.7	55.2±6.0
身高(m)	1.65±0.09	1.67±0.08	1.66±0.05
BMI(kg/m²)	47.8±8.0*	44.6±8.8*	19.3±1.1

参数	I组（n=12）	II组（n=11）	III组（n=6）
年龄	30.9±7.5	30.2±7.3	28.8±10.8
体重(kg)	121.6±43.6	124.1±26.7	55.2±6.0
身高(m)	1.65±0.09	1.67±0.08	1.66±0.05
BMI(kg/m²)	47.8±8.0*	44.6±8.8*	19.3±1.1

项目	组别	麻醉前（T1）	停丙泊酚24 h（T3）	停丙泊酚72 h（T4）
T(U/ L)	I组	53.1±66.1	36.8±15.9	30.3±14.7
?	II组	38.2±29.1	45.3±30.7	36.8±20.6
?	III组	20.5±8.5	21.3±3.0	23.5±8.1
ALT(U/ L)	I组	69.6±56.2	66.2±44.2	59.6±37.7
?	II组	55.9±42.9	59.0±41.2	48.6±37.3
?	III组	28.7±24.5	36.3±34.2	37.2±27.7
LDH(U/ L)	I组	164.5±44.4	180.3±83.2	161.4±28.0
?	II组	173.1±32.0	193.2±37.2	174.2±64.5
?	III组	160.8±33.4	149.8±34.9	160.3±31.8
TB(μmo l/L)	I组	9.8±4.1	10.5±3.0	10.1±2.6
?	II组	12.4±2.0	12.6±2.0	12.5±3.2
?	III组	11.0±4.0	10.3±2.6	9.4±2.2
TC(mmo l/L)	I组	5.23±0.91	5.45±1.05	5.35±1.33
?	II组	4.91±1.02	5.18±1.24	4.92±1.44
?	III组	4.85±0.54	5.23±0.78	4.92±0.95
TG(mmo l/L)	I组	2.17±0.05	2.36±0.85	2.62±1.24
?	II组	2.18±0.75	2.68±1.05	2.50±1.43
?	III组	1.87±1.02	1.67±0.93	1.98±1.23
ALB(U/ L)	I组	45.5±3.2*	37.5±3.8*△	37.0±3.3*△
?	II组	45.6±3.8*	38.1±3.7*△	38.8±5.3*△
?	III组	54.5±3.2	45.7±3.3△	46.0±4.3△
BUN(mmol/L)	I组	4.25±0.91	3.39±1.16△	3.37±0.81△
?	II组	4.15±1.10	3.18±1.19△	3.49±1.16△
?	III组	4.39±0.86	3.25±0.85△	3.40±0.47△
Scr(mmo l/L)	I组	74.3±6.2	75.2±6.5	75.4±6.9
?	II组	74.6±13.6	84.9±17.3	83.9±25.9
?	III组	79.7±7.3	79.8±10.8	77.3±8.2
CK(U/ L)	I组	167.4±138	184.9±128.8	180.9±125.0
?	II组	107.8±53.2	222.0±173.3	153.8±147.0
?	III组	132.5±71.5	180.0±124.5	234.2±197.1

项目	组别	麻醉前（T1）	停丙泊酚24 h（T3）	停丙泊酚72 h（T4）
T(U/ L)	I组	53.1±66.1	36.8±15.9	30.3±14.7
?	II组	38.2±29.1	45.3±30.7	36.8±20.6
?	III组	20.5±8.5	21.3±3.0	23.5±8.1
ALT(U/ L)	I组	69.6±56.2	66.2±44.2	59.6±37.7
?	II组	55.9±42.9	59.0±41.2	48.6±37.3
?	III组	28.7±24.5	36.3±34.2	37.2±27.7
LDH(U/ L)	I组	164.5±44.4	180.3±83.2	161.4±28.0
?	II组	173.1±32.0	193.2±37.2	174.2±64.5
?	III组	160.8±33.4	149.8±34.9	160.3±31.8
TB(μmo l/L)	I组	9.8±4.1	10.5±3.0	10.1±2.6
?	II组	12.4±2.0	12.6±2.0	12.5±3.2
?	III组	11.0±4.0	10.3±2.6	9.4±2.2
TC(mmo l/L)	I组	5.23±0.91	5.45±1.05	5.35±1.33
?	II组	4.91±1.02	5.18±1.24	4.92±1.44
?	III组	4.85±0.54	5.23±0.78	4.92±0.95
TG(mmo l/L)	I组	2.17±0.05	2.36±0.85	2.62±1.24
?	II组	2.18±0.75	2.68±1.05	2.50±1.43
?	III组	1.87±1.02	1.67±0.93	1.98±1.23
ALB(U/ L)	I组	45.5±3.2*	37.5±3.8*△	37.0±3.3*△
?	II组	45.6±3.8*	38.1±3.7*△	38.8±5.3*△
?	III组	54.5±3.2	45.7±3.3△	46.0±4.3△
BUN(mmol/L)	I组	4.25±0.91	3.39±1.16△	3.37±0.81△
?	II组	4.15±1.10	3.18±1.19△	3.49±1.16△
?	III组	4.39±0.86	3.25±0.85△	3.40±0.47△
Scr(mmo l/L)	I组	74.3±6.2	75.2±6.5	75.4±6.9
?	II组	74.6±13.6	84.9±17.3	83.9±25.9
?	III组	79.7±7.3	79.8±10.8	77.3±8.2
CK(U/ L)	I组	167.4±138	184.9±128.8	180.9±125.0
?	II组	107.8±53.2	222.0±173.3	153.8±147.0
?	III组	132.5±71.5	180.0±124.5	234.2±197.1

项目	组别	麻醉前（T1）	停丙泊酚6 h（T2）	停丙泊酚24 h（T3）
B2-MG（mg/L）	I组	1.80±0.65	1.12±0.67△	1.07±0.65△
?	II组	1.93±0.38	1.07±0.30△	1.02±0.33△
?	III组	1.87±0.27	1.03±0.18△	1.09±0.25△

Please choose a citation manager

Content to export